Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GENB stock hub

Generate Biomedicines, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GENBis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GENB

In the news

Latest news · GENB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GENB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

162

Groups with data

Currency

USD

Showing 162 of 162 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002100782
Company name	Generate Biomedicines, Inc.
Country	United States
Country code	US
Cusip	370920100
Employees	312
Enterprise value	$1.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2026-02-27
Isin	US3709201004
Last refreshed	2026-05-10
Market cap	$1.7B
Market cap category	Small-Cap
Price	$13.66
Price currency	USD
Rev Per Employee	97,112.18x
Sector	Healthcare
Sic	2834
Symbol	GENB
Tags	pharmaceuticals
Website	https://generatebiomedicines.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-15.25%
EV/Sales	42.57x
FCF yield	-13.46%
P/B ratio	3.4x
P/S ratio	57.46x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-194.4M
Net Income	$-265.4M
Net Income Growth Years	0%
Pretax Margin	-792.86%
Profit Per Employee	$-850,772
ROCE	-44.24

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Years	0
Revenue Growth	55.89x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$625.7M
Cash	$516.6M
Current Assets	$535.4M
Current Liabilities	$58.4M
Debt	$65.6M
Debt Equity	$0.13
Equity	$514.8M
Interest Coverage	-264.2
Liabilities	$110.9M
Long Term Assets	$90.3M
Long Term Liabilities	$52.5M
Net Cash	$451.1M
Net Cash By Market Cap	$25.91
Net Debt Equity	$-0.88
Tangible Book Value	$514.8M
Tangible Book Value Per Share	$4.02

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.17
Net Working Capital	$-25.4M
Quick ratio	8.85
Working Capital	$477M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
All Time High	15.89
All Time High Change	-14.01%
All Time High Date	2026-05-06
All Time Low	11
All Time Low Change	24.18%
All Time Low Date	2026-03-04
ATR	1.06
Beta1y	1.22
High	14.65
High52	15.89
High52 Date	2026-05-06
High52ch	-14.01%
Low	13.36
Low52	11
Low52 Date	2026-03-04
Low52ch	24.18%
Premarket Change Percent	2.89
Premarket Price	$13.98
Premarket Volume	519
RSI	54.26
RSI Monthly	0
RSI Weekly	0
Sharpe ratio	0.85x
Sortino ratio	1.29
Tr1m	15.47%
Tr1w	3.88%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.48
Earnings Revenue Estimate	6,040,000x
Earnings Revenue Estimate Growth	-31.5x
Operating Income	$-251M
Operating margin	-828.5
Price target	$25
Price Target Change	$83.02
Price Target Change Top	$83.02

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	122,247,841%
Float Percent	95.92%
Net Borrowing	-6,630,000
Shares Insiders	4.08%
Shares Institutions	3.82%
Shares Out	127,450,201
Shares Qo Q	97.83%
Short Float	1.7%
Short Ratio	5.71
Short Shares	1.63

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-256.6M
Average Volume	322,310.3x
Bv Per Share	4.02
CAPEX	$-6.5M
Ch1m	15.47
Ch1w	3.88
Change	0.52%
Change From Open	-0.94
Close	13.59
Days Gap	1.47
Depreciation Amortization	13,037,000
Dollar Volume	3,981,808
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-251M
EBITDA	$-238M
EPS	$-4.57
F Score	1
FCF	$-234.4M
FCF EV Yield	-18.17x
FCF Per Share	$-1.84
Financing CF	386,390,000
Fiscal Year End	December
Founded	2,018
Income Tax	$135,000
Investing CF	-218,699,000
Ipr	-14.63
Iprfo	-8.93
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Ma20	13.11
Ma20ch	4.18%
Net CF	-60,140,000
Next Earnings Date	2026-08-03
Open	13.79
Optionable	No
Position In Range	23.26
Post Close	13.66
Postmarket Change Percent	3.15
Postmarket Price	$14.09
Ppne	85,602,000
Pre Close	13.59
Price Date	2026-05-08
Ptbv Ratio	3.38
Relative Volume	0.9x
Revenue	30,299,000x
SBC By Revenue	73.36x
Share Based Comp	22,228,000
Tax By Revenue	0.45x
Us State	Massachusetts
Volume	291,494

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GENB pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns GENB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.8%

Float: +95.9% of shares outstanding

Insider ownership

+4.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GENB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.3

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.85

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GENB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GENB stock rating?

Generate Biomedicines, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GENB analysis?

The full report lives at /stocks/GENB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GENB?

The latest report frames GENB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GENB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.